North China Pharmaceutical’s tacrolimus capsules, an immunosuppressant, have received a drug registration certificate.
January 27, 2026
Source: drugdu
44
On January 26, North China Pharmaceutical(600812) announced that it recently obtained a Drug Registration Certificate for Tacrolimus Capsules (0.5mg, 1mg) issued by the National Medical Products Administration. This drug is a prescription drug with an 18-month shelf life, and its registration standard number is YBH35192025. This approval indicates that the product meets the relevant requirements for drug registration and possesses the basic access conditions for centralized procurement bidding. Tacrolimus is a potent immunosuppressant, primarily used to prevent graft rejection after liver or kidney transplantation.
To date, excluding the original drug, eight domestic companies, including ours, hold drug registration certificates for tacrolimus capsules (0.5mg, 1mg). According to data from Yaorongyun's full-terminal hospital database, sales of tacrolimus capsules reached 5.292 billion yuan in 2024, with a sales volume of 472 million capsules.
In the first three quarters of 2025, North China Pharmaceutical Group achieved revenue of RMB 7.485 billion and net profit attributable to the parent company of RMB 159 million.
https://finance.eastmoney.com/a/202601263630773295.html
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Initial Clinical Exploration of D-0502 in Combination with ADC Therapies Officially Commenced. January 30, 2026
- Pfizer’s blockbuster drug receives notice of approval! January 30, 2026
- Aminophylline tablets pass generic drug consistency evaluation January 30, 2026
- Propafenone Hydrochloride Injection Receives Drug Production Registration Certificate January 30, 2026
- Hengrui’s innovative drug camrelizumab in combination with apatinib mesylate and TACE for the treatment of liver cancer has been accepted for marketing authorization application January 30, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
